Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.
Wayne Kuznar
Advertisement
Articles by Wayne Kuznar
Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.
The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.
Advertisement
Latest Updated Articles
First-in-Class Immunotoxin Shows Durable Response in Hairy Cell LeukemiaPublished: June 4th 2018 | Updated:
Cyramza Added to Chemo Regimen Not Found to Improve Gastric Cancer SurvivalPublished: January 22nd 2018 | Updated:
Nivolumab Shows Promise Treating Gastrointestinal TumorsPublished: January 22nd 2018 | Updated:
Keytruda Improves Progression-Free Survival in Advanced Hepatocellular CarcinomaPublished: January 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Regular Melatonin Supplementation May Hide Hidden Heart Complications
2
CDC Adolescents, Children, & Adult Immunization Schedule: 2025 Update
3
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
4
PCV21-Unique Serotypes Most Prevalent in US Adults With Pneumococcal Disease
5
